Genomic Determinants of Drug-Induced Mitochondrial Translation Inhibition

Abstract

Drug-induced mitochondrial translation inhibition is an increasingly recognized mechanism of organ toxicity, particularly affecting tissues with high oxidative phosphorylation demands, including skeletal muscle, myocardium, kidney, liver, retina, and the nervous system. Mitochondrial protein synthesis depends on a specialized translation apparatus encoded partly by the mitochondrial genome and partly by nuclear genes. Pharmacological interference with this system may arise from direct inhibition of mitochondrial ribosomes, disruption of mitochondrial tRNA maturation, impaired aminoacylation, altered mitoribosome assembly, or defective mitochondrial quality-control responses. Genomic determinants influence both susceptibility and clinical severity. These determinants include pathogenic mitochondrial DNA variants, nuclear gene variants affecting mitochondrial translation, haplogroup background, copy-number heteroplasmy, pharmacokinetic genes, and regulatory variants that modify drug exposure or cellular stress responses. The clinical phenotype is shaped by tissue-specific heteroplasmy thresholds, age, comorbidity, cumulative dose, treatment duration, and coadministration of other mitochondrial toxicants. Recognition requires integration of medication history, biochemical testing, imaging, electrophysiology, molecular diagnostics, and, in selected cases, tissue assessment. Management depends on withdrawal or substitution of the suspected drug, supportive treatment, correction of metabolic stressors, and specialist evaluation. Genomic risk stratification is not yet routine for most medications, but advances in long-read sequencing, single-cell genomics, functional mitochondrial assays, and pharmacogenomics are expected to improve prediction, diagnosis, and individualized treatment.

Introduction

Mitochondrial translation is essential for production of the thirteen polypeptides encoded by mitochondrial DNA, all of which are core subunits of respiratory-chain complexes involved in oxidative phosphorylation. Unlike cytosolic translation, mitochondrial protein synthesis uses distinct ribosomal proteins, transfer RNAs, aminoacyl-tRNA synthetases, initiation and elongation factors, and quality-control mechanisms. Consequently, medications that interfere with bacterial-like mitochondrial ribosomes or with mitochondrial RNA metabolism can produce clinically important toxicity even when cytosolic protein synthesis is preserved.

The genomic basis of this vulnerability is complex. Mitochondrial DNA is maternally inherited, present in multiple copies per cell, and frequently exists as a mixture of normal and pathogenic genomes known as heteroplasmy. Nuclear genes encode most components of the mitochondrial translation system and regulate mitochondrial replication, RNA processing, ribosome assembly, proteostasis, and stress signaling. A patient may therefore develop toxicity because of a previously silent mitochondrial DNA variant, a nuclear disease allele, a drug-metabolizing genotype that increases systemic exposure, or an interaction between several modest-risk factors. This review summarizes the disease burden, mechanisms, clinical presentation, diagnostic approach, management principles, and emerging genomic strategies relevant to drug-induced mitochondrial translation inhibition.

Epidemiology / Disease Burden

The precise incidence of drug-induced mitochondrial translation inhibition is difficult to determine because manifestations are heterogeneous, often delayed, and commonly attributed to more prevalent disorders such as diabetes, inflammatory myopathy, viral illness, renal disease, or adverse effects unrelated to mitochondria. Burden is greatest in patients receiving prolonged antimicrobial, antiviral, antineoplastic, or immunomodulatory therapy, although clinically significant injury can occur after shorter exposures in genetically susceptible individuals. Nucleoside and nucleotide analogues, selected antibiotics, antiretroviral agents, and other compounds with mitochondrial ribosome or mitochondrial DNA effects have been associated with myopathy, neuropathy, lactic acidosis, hepatic injury, cardiomyopathy, or bone-marrow abnormalities.

Subclinical mitochondrial dysfunction may be substantially more common than severe toxicity. Mild increases in lactate, reduced exercise tolerance, fatigue, or asymptomatic reductions in respiratory-chain activity can precede overt organ injury. Underdiagnosis is also promoted by incomplete phenotyping and limited access to genomic testing. The burden is potentially amplified by an aging population, polypharmacy, chronic kidney or liver disease, and the increasing use of combination regimens. Population-level risk varies according to mitochondrial haplogroup distribution, prevalence of pathogenic variants, prescribing practices, and availability of pharmacovigilance systems.

Pathophysiology

Drug-induced mitochondrial translation inhibition reduces synthesis of mitochondrially encoded respiratory-chain subunits. Incomplete assembly of complexes I, III, IV, or V impairs electron transport and lowers ATP generation. Electron leakage can increase reactive oxygen species, while impaired membrane potential disrupts calcium handling, mitochondrial protein import, and apoptotic regulation. Cells may compensate through glycolysis, mitochondrial biogenesis, and mitophagy, but persistent stress eventually produces energy failure, membrane injury, inflammation, and cell death.

Genomic determinants act at several levels. Pathogenic mitochondrial DNA variants may reduce the functional reserve of respiratory-chain complexes, allowing a drug-induced translational defect to cross a tissue-specific threshold. Heteroplasmy is particularly important because symptoms may emerge when the proportion of mutant mitochondrial genomes exceeds a critical level, although this threshold differs among tissues and variants. Nuclear variants in genes encoding mitochondrial aminoacyl-tRNA synthetases, ribosomal proteins, RNA-modifying enzymes, translational factors, and mitochondrial proteases can produce partial defects that remain compensated until pharmacological stress occurs.

Drug properties also influence injury. Some compounds bind mitochondrial ribosomal RNA or proteins, whereas others inhibit mitochondrial DNA polymerase, deplete nucleotide pools, alter tRNA charging, or impair membrane transport. Variants in pharmacokinetic genes, renal transporters, hepatic enzymes, or drug targets may increase intracellular exposure. In addition, inflammatory signaling, oxidative stress, nutritional deficiency, and impaired autophagy can reduce the capacity to recover from translational inhibition. The resulting phenotype is therefore a pharmacogenomic and systems-level event rather than a simple consequence of one mutation.

Risk Factors

Important risk factors include a personal or maternal family history of mitochondrial disease, unexplained exercise intolerance, sensorineural hearing loss, diabetes with multisystem features, cardiomyopathy, seizures, migraine, ptosis, ophthalmoplegia, or recurrent lactic acidosis. Known mitochondrial DNA or nuclear gene variants substantially increase concern, but their absence on routine testing does not exclude susceptibility. Older age, low body mass, malnutrition, pregnancy, renal or hepatic dysfunction, and high cumulative drug exposure may increase tissue concentrations or reduce metabolic reserve.

Concomitant mitochondrial toxicants are clinically important. Combination antimicrobial or antiviral therapy, alcohol exposure, corticosteroid-associated metabolic stress, uncontrolled diabetes, severe infection, and other causes of hypoxia may convert compensated dysfunction into symptomatic disease. The risk may also depend on mitochondrial haplogroup and tissue-specific heteroplasmy, which are not routinely incorporated into prescribing decisions. A careful baseline assessment is particularly valuable when therapy is prolonged or when the anticipated benefit must be balanced against potentially irreversible neuromuscular, cardiac, or hepatic injury.

Clinical Features

Clinical manifestations reflect the organs most dependent on oxidative phosphorylation. Patients may report new fatigue, exercise intolerance, myalgia, proximal weakness, cramps, peripheral neuropathy, paresthesia, or gait impairment. More serious presentations include rhabdomyolysis, respiratory muscle weakness, encephalopathy, seizures, cardiomyopathy, conduction abnormalities, optic neuropathy, sensorineural hearing loss, pancreatitis, hepatic dysfunction, renal tubular injury, or lactic acidosis. Some patients develop a multisystem syndrome resembling a primary mitochondrial disorder.

Timing is variable. Symptoms may arise within days in patients with severe pre-existing vulnerability, but delayed onset after weeks or months is common. Clinical deterioration can continue briefly after the drug is stopped because damaged mitochondria and affected tissues require time to recover. A mismatch between the severity of symptoms and conventional laboratory findings should not be dismissed. Conversely, abnormal lactate or creatine kinase levels are nonspecific and must be interpreted with examination findings, medication exposure, and alternative diagnoses.

Diagnosis

Diagnosis begins with a structured medication history that records start dates, dose changes, cumulative exposure, renal and hepatic function, interacting drugs, supplements, and previous unexplained episodes. Baseline and follow-up assessment may include complete blood count, electrolytes, renal and hepatic profiles, creatine kinase, lactate, glucose, venous or arterial blood gas analysis, urinalysis, and biomarkers appropriate to the suspected organ system. Electrocardiography, echocardiography, nerve-conduction studies, electromyography, ophthalmologic examination, pulmonary testing, or magnetic resonance imaging may be indicated.

Genetic evaluation should be guided by phenotype and family history. Testing may include mitochondrial DNA sequencing with heteroplasmy quantification, deletion and duplication analysis, nuclear multigene panels, exome sequencing, or genome sequencing. Blood may underestimate heteroplasmy because mutant load can be higher in urine epithelial cells, buccal cells, skeletal muscle, or other affected tissues. Long-read and high-depth sequencing can improve detection of low-level heteroplasmy and complex rearrangements. Functional studies, such as respiratory-chain enzyme analysis, oxygen-consumption measurements, mitochondrial translation assays, or fibroblast testing, can help determine whether a variant is biologically relevant. A temporal relationship to drug exposure and improvement after withdrawal support causality but are not individually diagnostic.

Treatment & Management

The first management step is urgent review of the suspected medication and, when clinically feasible, discontinuation or substitution with an effective non-mitochondrial-toxic alternative. Decisions should consider infection control, cancer treatment goals, antiviral resistance, and the seriousness of organ injury. Severe lactic acidosis, rhabdomyolysis, cardiomyopathy, encephalopathy, or respiratory failure requires hospital-based care and specialist involvement. Renal and hepatic dysfunction should be corrected where possible because impaired clearance can intensify toxicity.

Supportive treatment includes hydration when appropriate, correction of electrolyte and glucose disturbances, nutritional optimization, treatment of heart failure or arrhythmia, physical and occupational rehabilitation, and management of neuropathic pain. Standard mitochondrial supplements may be considered in selected patients, but evidence for routine use in drug-induced translation inhibition remains limited and should not replace removal of the offending exposure. Rechallenge is generally avoided after severe or multisystem toxicity. If treatment is essential, a multidisciplinary risk-benefit assessment with close biochemical and clinical monitoring is required.

Recent Advances / Emerging Therapies

Recent research is moving toward integrated pharmacogenomics that combines mitochondrial DNA heteroplasmy, nuclear variants, haplogroup, transcriptomic signatures, and drug-exposure data. High-throughput cellular models can identify compounds that selectively impair mitochondrial translation and can test patient-derived cells for drug sensitivity. Single-cell sequencing may clarify why tissues with similar heteroplasmy levels develop different clinical outcomes. Long-read sequencing is improving characterization of mitochondrial rearrangements and low-level variant mixtures that were previously missed.

Emerging therapeutic concepts include agents that enhance mitochondrial biogenesis, stabilize respiratory-chain assembly, reduce oxidative injury, improve mitophagy, or modulate mitochondrial proteostasis. Precision approaches aimed at selectively eliminating pathogenic mitochondrial genomes, including targeted nuclease and base-editing strategies, remain experimental and are not established treatments for drug toxicity. Biomarkers based on circulating mitochondrial DNA, metabolomics, or tissue-specific translational stress could eventually identify injury before irreversible organ damage. Clinical validation, standardized outcome measures, and careful assessment of off-target effects remain necessary before these approaches can enter routine practice.

Guideline Recommendations

Current clinical practice should follow established principles of adverse drug reaction management, pharmacovigilance, mitochondrial disease evaluation, and organ-specific care. Before prolonged therapy with a recognized mitochondrial toxicant, clinicians should document baseline symptoms, review family history, assess renal and hepatic function, and consider targeted genetic consultation when the phenotype suggests inherited mitochondrial disease. During treatment, new fatigue, myopathy, neuropathy, visual symptoms, hearing change, unexplained gastrointestinal illness, cardiopulmonary symptoms, or altered mental status should prompt reassessment rather than routine continuation.

Patients with significant lactate elevation, progressive weakness, marked creatine kinase increase, organ dysfunction, or suspected multisystem toxicity should receive prompt specialist review. Drug cessation or substitution should be considered when a plausible causal relationship exists, particularly if symptoms are progressive. Genomic findings must be interpreted by experienced professionals because variants of uncertain significance, tissue-specific heteroplasmy, and incomplete penetrance can lead to inappropriate treatment changes. Documentation and reporting of suspected reactions improve safety surveillance and help refine future prescribing guidance. At present, universal pre-treatment mitochondrial genomic screening is not recommended for most drugs because predictive evidence, cost-effectiveness, and actionable thresholds remain insufficient.

Conclusion

Drug-induced mitochondrial translation inhibition arises from the interaction of pharmacological exposure with mitochondrial and nuclear genomic architecture, tissue-specific energy requirements, and patient-level metabolic reserve. Heteroplasmy, pathogenic variants in translation-related genes, haplogroup background, pharmacokinetic variation, comorbidity, and cumulative exposure can determine whether mitochondrial stress remains compensated or progresses to clinically significant organ injury. Early recognition requires detailed medication review, awareness of multisystem presentations, appropriate biochemical testing, and selective use of advanced genomic and functional studies. Withdrawal or substitution of the offending agent remains the central intervention, supported by organ-directed care and multidisciplinary follow-up. As sequencing technologies and functional pharmacogenomic models mature, genomic risk assessment may become more precise, enabling safer drug selection, earlier monitoring, and individualized prevention of mitochondrial toxicity.